| View |
|
BR-1215
|
Peginterferon alfa-2a
|
PEGNANO
|
180mcg/ 0.5 mL
|
Solution for S.C. Injection
|
IMMUNOSTIMULANT
|
Nanogen Pharmaceutical Biotechnology Co. Ltd
|
Vietnam
|
Automatic Renewal
|
24 January 2022
|
02 May 2027
|
| View |
|
BR-1216
|
RECOMBINANT HUMAN ERYTHROPOIETIN
|
DYPOTIN
|
4000 IU/ mL (PRE-FILLED SYRINGE)
|
Solution for Injection
|
HEMATOPOIETIC GROWTH FACTOR
|
NCPC Genetech Biotechnology Co., Ltd
|
China
|
Automatic Renewal
|
29 March 2022
|
09 May 2027
|
| View |
|
BR-1217
|
Streptokinase
|
None
|
1,500,000 IU
|
Powder For Injection (IV)
|
-
|
Dae Han New Pharm. Co., LTD.
|
Korea
|
Renewal
|
27 October 2022
|
21 May 2026
|
| View |
|
BR-1218
|
Isophane Insulin Human
|
Insulatard
|
100 IU/mL
|
Solution for Injection (SC)
|
Intermediate Acting Insulin
|
Novo Nordisk Production SAS
|
France
|
Automatic Renewal
|
26 March 2022
|
02 June 2027
|
| View |
|
BR-1219
|
Insulin Human (Regular)
|
Actrapid
|
100 IU/mL
|
Solution for Injection (SC)
|
Short Acting Insulin
|
Novo Nordisk Production SAS
|
France
|
Automatic Renewal
|
31 March 2022
|
02 June 2027
|
| View |
|
BR-1220
|
Biphasic Insulin
|
Mixtard 30
|
100 IU/mL
|
Suspension for Injection (SC)
|
Intermediate Acting Insulin
|
Novo Nordisk Production SAS
|
France
|
Renewal
|
31 March 2022
|
02 June 2027
|
| View |
BR-1221_PI_01.pdf
|
BR-1221
|
Adalimumab
|
Humira
|
40 mg /0.4 mL
|
Solution for Injection (SC)
|
-
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
Initial (from Monitored Release)
|
05 August 2022
|
17 July 2027
|
| View |
|
BR-1222
|
Pegfilgrastim
|
Neulastim
|
6 mg/0.6 mL
|
Solution For Injection (SC)
|
-
|
Amgen Manufacturing Limited
|
U.S.A
|
-
|
18 March 2022
|
14 July 2027
|
| View |
|
BR-1223
|
Filgrastim
|
Neupogen
|
300 mcg/mL
|
Solution For Injection (SC/IV)
|
-
|
Amgen Manufacturing Limited
|
U.S.A
|
-
|
18 March 2022
|
14 July 2027
|
| View |
|
BR-1224
|
Filgrastim
|
Biofil
|
300 mcg/mL
|
Solution For Injection (IV/SC)
|
-
|
Sinergium Biotech S.A.
|
Argentine Republic
|
Renewal
|
26 August 2022
|
08 August 2027
|
| View |
BR-1225_PI_01.pdf
|
BR-1225
|
Insulin Degludec + Liraglutide
|
Xultophy
|
100 U/3.6 mg/mL
|
Solution for Injection (SC)
|
-
|
Novo Nordisk A/S
|
Denmark
|
Initial (from Monitored Release)
|
24 October 2022
|
10 August 2027
|
| View |
|
BR-1226
|
Insulin Detemir
|
Levemir Penfill
|
100 U/ml
|
Solution for injection
|
Insulin and analogue for injection, long-acting
|
Novo Nordisk A/S
|
Denmark
|
Renewal
|
09 June 2022
|
05 September 2027
|
| View |
|
BR-1232
|
Botulinum Toxin Type A (from Clostridium botulinum)
|
Xeomin
|
50 Units
|
Powder For Solution For Injection (IM)
|
Muscle Relaxant
|
IDT Biologika GmbH
|
Germany
|
Automatic Renewal
|
30 August 2022
|
19 September 2027
|
| View |
|
BR-1233
|
Botulinum Toxin Type A (from Clostridium botulinum)
|
Xeomin
|
100 units
|
Powder For Solution For Injection (IM)
|
Muscle Relaxant
|
Merz Pharma GmbH & co. KGaA
|
Germany
|
Automatic Renewal
|
30 August 2022
|
19 September 2027
|
| View |
|
BR-1234
|
Botulinum Toxin* Type A (*from Clostridium botulinum)
|
Xeomin
|
50 Units
|
Powder for Solution for Injection (IM)
|
Muscle Relaxant
|
Merz Pharma GmbH & Co. KGaA
|
Germany
|
Renewal
|
25 August 2022
|
19 September 2027
|
| View |
|
BR-1235
|
Isophane Insulin Human, Recombinant DNA
|
Jusline N
|
100 units/mL
|
Sterile Suspension For Injection ( Sc )
|
Intermediate-acting Insulin
|
Gulf Pharmaceutical Industries ( Julphar )
|
UAE
|
Renewal
|
28 March 2023
|
14 March 2028
|
| View |
|
BR-1236
|
Regular Insulin Human, Recombinant DNA
|
Jusline R
|
100 units/mL
|
Sterile Suspension For Injection ( Sc )
|
Short-acting Insulin
|
Gulf Pharmaceutical Industries ( Julphar )
|
UAE
|
Renewal
|
20 March 2023
|
14 March 2028
|
| View |
|
BR-1237
|
Neutral Insulin Human + Isophane Insulin Human, Recombinant DNA
|
Jusline 30/70
|
100 units/mL ( 30% as neutral insulin human/ 70% as isophane insulin human )
|
Sterile Suspension For Injection ( Sc )
|
Intermediate-acting Insulin
|
Gulf Pharmaceutical Industries ( Julphar )
|
UAE
|
Renewal
|
22 March 2023
|
14 March 2028
|
| View |
|
BR-1240
|
Trastuzumab
|
Hertraz
|
150 mg
|
Powder for Concentrate for Solution for Infusion
(IV)
|
Monoclonal Antibodies
|
Biocon Biologics India Limited
|
India
|
Initial (from Monitored Release)
|
29 March 2023
|
05 October 2027
|
| View |
|
BR-1241
|
Trastuzumab
|
Hertraz
|
440 mg
|
Powder For Concentrate For Solution For Infusion
|
Monoclonal Antibodies
|
Biocon Limited
|
India
|
Initial (from Monitored Release)
|
18 August 2022
|
05 October 2027
|